Maze Therapeutics, Inc.
MAZEDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
MAZE Earnings Report
EPS Est: $-0.76 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How MAZE's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Maze Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Maze Therapeutics, Inc.'s (MAZE) pipeline across Phase 2. Its lead program is MZE829 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Maze Therapeutics, Inc.'s next FDA catalyst?→
Maze Therapeutics, Inc.'s (MAZE) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MAZE biotech catalysts?→
Add MAZE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Maze Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.